Max Robotics — Global Service Robot Directory + US Certification

About

Maurits Wondergem is a leading clinical researcher in nuclear medicine and oncology, specializing in the application of prostate-specific membrane antigen (PSMA) PET/CT imaging for prostate cancer management. His work has fundamentally advanced the accuracy of staging and restaging in this disease. Wondergem’s most impactful contribution is the landmark SALT trial (2020, 106 citations), which demonstrated the high diagnostic accuracy of 18F-DCFPyL PSMA PET/CT for detecting pelvic lymph-node metastases prior to extended dissection in primary prostate cancer, validating its role over conventional imaging. He has also investigated the modality’s utility in local staging (2024) and its profound impact on clinical management decisions for patients with biochemical recurrence after definitive treatment (2021, 15 citations). His research consistently shows how PSMA PET/CT guides salvage therapy strategies, improving patient stratification. With a cumulative citation count exceeding 145 from his top works, Wondergem’s studies provide essential evidence for integrating PSMA PET/CT into standard oncologic pathways, directly influencing surgical and radiotherapy planning for thousands of patients worldwide.